Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes - Centre de recherche Saint-Antoine - UMR S938 Accéder directement au contenu
Article Dans Une Revue Cell Reports Medicine Année : 2020

Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes

Résumé

Plasma dihydroceramides are predictors of type 2 diabetes and related to metabolic dysfunctions, but the underlying mechanisms are not characterized. We compare the relationships between plasma dihydroceramides and biochemical and hepatic parameters in two cohorts of diabetic patients. Hepatic steatosis, steatohepatitis, and fibrosis are assessed by their plasma biomarkers. Plasma lipoprotein sphingolipids are studied in a sub-group of diabetic patients. Liver biopsies from subjects with suspected non-alcoholic fatty liver disease are analyzed for sphingolipid synthesis enzyme expression. Dihydroceramides, contained in triglyceride-rich very-low-density lipoprotein (VLDL), are associated with steatosis and steatohepatitis. Expression of sphingolipid synthesis enzymes is correlated with histological steatosis and inflammation grades. In conclusion, association of plasma dihydroceramides with nonalcoholic fatty liver might explain their predictive character for type 2 diabetes. Our results suggest a relationship between hepatic sphingolipid metabolism and steatohepatitis and an involvement of dihydroceramides in the synthesis/secretion of triglyceride-rich VLDL, a hallmark of NAFLD and type 2 diabetes dyslipidemia.
Fichier principal
Vignette du fichier
1-s2.0-S2666379120302019-main.pdf (3.48 Mo) Télécharger le fichier
Origine : Publication financée par une institution

Dates et versions

hal-03099637 , version 1 (06-01-2021)

Identifiants

Citer

Aurélie Carlier, Franck Phan, Anaïs Szpigel, Eric Hajduch, Joe-Elie Salem, et al.. Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes. Cell Reports Medicine, 2020, 1 (9), pp.100154. ⟨10.1016/j.xcrm.2020.100154⟩. ⟨hal-03099637⟩
112 Consultations
45 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More